Total Funding
48
52
Total FundingPost-IPO Equity raised
Growth Score
-11 pts
Heat Score
20 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
29935
Cullinan Therapeutics is a developer of an externally sourced cancer therapeutics used to end a drug program quickly.
- Mary Fenton: Chief Financial OfficerPast Role: Talaris Therapeutics, President and Interim Chief Executive Officer
Jon Wigginton: Chairman SAB and Senior AdvisorPast Role: MacroGenics, Senior Vice President, Clinical Development
About the Company
Cullinan Therapeutics is a developer of an externally sourced cancer therapeutics intended to end a drug program quickly if the early research suggests it won't work. The company's therapeutics are developed via assets sourced internally through dry lab or externally through business, academic and pharma collaborations, enabling
researchers to get a highly diversified portfolio of oncology therapeutics with a unique, cost-efficient business model.
